The goal of this clinical trial is to compare 1% and 3% diclofenac gel (DARE-PDM1) to placebo in women with symptomatic primary dysmenorrhea. The main question it aims to answer are: Is DARE-PDM1 1%, 3% diclofenac gel systemically safe? What are the systemic levels of DARE-PDM1 1%, 3% diclofenac gel in plasma and vaginal fluid following 1 dose and 3 doses. Participants will be seen for routine safety evaluations and complete a daily diary recording dysmenorrhea associated pain.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
42
vaginal hydrogel containing 1% Diclofenac
vaginal hydrogel containing 3% Diclofenac
vaginal hydrogel, no active ingredient
PARC Clinical Research
Adelaide, Western Australia, Australia
Measure the systemic Level of Diclofenac after a single dose of DARE-PDM1
Evaluate the plasma pharmacokinetics of diclofenac after a single dose of DARE-PDM1
Time frame: 7 days
Measure the systemic Level of Diclofenac after three doses of DARE-PDM1
Evaluate the plasma pharmacokinetics of diclofenac after three doses of DARE-PDM1
Time frame: 3 days
Measure the Vaginal Fluid levels of diclofenac after three doses of DARE-PDM1
Evaluate the vaginal fluid pharmacokinetics of diclofenac after three doses of DARE-PDM1
Time frame: 3 days
Measure the Vaginal Fluid levels of diclofenac after a single dose DARE-PDM1
Evaluate the vaginal fluid pharmacokinetics of diclofenac after a single dose of DARE-PDM1
Time frame: 7 days
Number of participants with abnormal vaginal exam findings.
Compare genital safety of DARE-PDM1 versus placebo through vaginal exams
Time frame: 60 days
Number of participants with abnormal laboratory test results.
Evaluate systemic safety of DARE-PDM1 versus placebo through safety laboratory assessments
Time frame: 60 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.